Diagnostic Significance of Selected Plasma MicroRNAs in Myelodysplastic Syndromes.

Svilena Atanasova, Trifon Chervenkov, Maria Teneva, Stela Dimitrova, Ilina Micheva

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Svilena AtanasovaHematology Clinic, University Hospital "St. Marina", Medical University, 9000 Varna, Bulgaria.ORCID 0000-0001-8939-8972

Trifon ChervenkovDepartment of Medical Genetics, Medical University, 9000 Varna, Bulgaria.

Maria TenevaLaboratory of Clinical Immunology, University Hospital "St. Marina", 9000 Varna, Bulgaria.

Stela DimitrovaHematology Clinic, University Hospital "St. Marina", Medical University, 9000 Varna, Bulgaria.

Ilina MichevaHematology Clinic, University Hospital "St. Marina", Medical University, 9000 Varna, Bulgaria.

Funding

Fund Nauka, Medical university "Prof. Dr Paraskev Stoyanov" Varna, Bulgaria 22001

6 · The paper itself

Abstract

Myelodysplastic syndromes (MDSs) are clonal hematopoietic disorders characterized by ineffective hematopoiesis and their diagnosis remains challenging, requiring integration of clinical, morphological, and genetic data. MicroRNAs (miRNAs) have emerged as potential biomarkers in MDS, offering insights into disease mechanisms and patient stratification. This study aimed to evaluate the diagnostic and prognostic significance of five plasma microRNAs (miR-22-3p, miR-144-3p, miR-16-5p, let-7a-5p, and miR-451a) in 40 patients with MDS, diagnosed according to WHO 2016 criteria and stratified by R-IPSS, and ten healthy controls. Plasma miRNA levels were measured by RT-qPCR. Expression profiles were compared between patients and controls, and further assessed in relation to disease subtypes, risk categories, and clinicopathological features. Expression analysis showed that miR-144-3p, miR-16-5p, let-7a-5p, and miR-451a were significantly lower in MDS patients compared to controls. MiR-451a demonstrated the highest diagnostic predictive value (

Indexed as

MicroRNAsMyelodysplastic SyndromesAdultAgedAged, 80 and overBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedPrognosisBiomarkersMicroRNAsMIRN144 microRNA, humanMIRN451 microRNA, humanbiomarkersmicroRNAsmyelodysplastic syndromes

Identifiers

PMID41828474

DOI10.3390/ijms27052250

PMCPMC12984662

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.